Status | Study |
Terminated |
Study Name: Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1) Condition: Plexiform Neurofibroma Associated With Neurofibromatosis Type 1 Date: 2011-05-27 Interventions: Drug: Everolimus (RAD001) oral daily dosing of tablet starting with 2.5 mg |
Recruiting |
Study Name: AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors Condition: Neurofibromatosis 1 Neurofibromatosis Type 1 NF 1 Date: 2011-05-27 Interventions: Drug: AZD6244 AZD6244 orally every 12 hours on continuous daily schedule for cycles of 28 days until una |
Completed |
Study Name: Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas Condition: Neurofibromatosis NF1 Neurofibromas Date: 2011-01-11 Interventions: Drug: Tasigna Following enrollment each subject will initially receive Tasigna orally at 200 mg twice da |
Active, not recruiting |
Study Name: Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas Condition: Neurofibromatosis Neurofibromas Date: 2010-06-08 Interventions: Drug: Gleevec Gleevec will be dosed orally with a starting dose of 100 mg twice daily for patients with |
Completed |
Study Name: Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas Condition: Neurofibromatosis Type I Plexiform Neurofibroma Date: 2008-07-31 Interventions: Drug: Nexavar (BAY 43-9006) (Sorafenib) Dr |
Active, not recruiting |
Study Name: Study of PEG-Intron for Plexiform Neurofibromas Condition: Plexiform Neurofibroma Date: 2006-11-02 Interventions: Drug: PEG-Intron |
Completed |
Study Name: R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas Condition: Neurofibroma, Plexiform Neurofibromatosis Type I Date: 2006-06-19 Interventions: Drug: tipifarnib Given orally, |
Completed |
Study Name: Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development Condition: Cancer Date: 2006-06-19 |
Active, not recruiting |
Study Name: AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine Condition: Neurofibromatosis Type 1 Plexiform Neurofibroma Date: 2006-05-16 Interventions: Drug: Cediranib Maleate Other Names: AZD2171 AZD2171 Maleate |
Completed |
Study Name: PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma Condition: Neoplasm of Uncertain Malignant Potential Unspecified Childhood Solid Tumor, Protocol Specif Date: 2005-11-11 Interventions: Biological: PEG-interferon alfa-2a |